I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Core Viewpoint - I-Mab has appointed Sean (Xi-Yong) Fu, PhD, MBA as the permanent CEO effective November 1, 2024, after serving as Interim CEO since July 15, 2024, which is seen as a significant step towards advancing the company's mission in cancer immunotherapy [1][2]. Company Overview - I-Mab is a U.S.-based global biotech company focused on developing highly differentiated immunotherapies for cancer treatment, with operations in Rockville, Maryland, and Short Hills, New Jersey [3]. Leadership and Experience - Dr. Fu has over 20 years of experience in the life sciences industry, including roles as Operating Partner at ABio-X and co-founder and CEO of RVAC Medicines, with a strong background in clinical-stage asset development and organizational leadership [2]. - His previous experience includes a 15-year tenure at Merck & Co., where he managed finances for late-stage clinical portfolios and led the integration of global R&D following a $42 billion merger [2]. Strategic Vision - Dr. Fu expressed excitement about leading I-Mab and emphasized the team's dedication to advancing their differentiated portfolio of immunotherapies, aiming to reach important upcoming milestones [2].